The Valley Desk

NCT05139017 · Interventional trial

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Overall registry status Recruiting

Phase 2 · Phase 3

Conditions DLBCL, Diffuse Large B-Cell Lymphoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov